Laboratory Outcome Predictors in Coronary Surgery - Full Text View

Purpose

Evaluate less employed markers of tissue hypoperfusion as venoarterial carbon dioxide partial pressure difference (ΔPCO2) and estimated respiratory quotient (eRQ) combined to other classically studied markers as predictive factors of complicated clinical course after cardiac surgery in patients with left ventricular dysfunction.

Condition
Left Ventricular Dysfunction Coronary Artery Bypass Surgery Tissue Hypoperfusion


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Markers of Tissue Perfusion as Predictors of Complicated Evolution in Patients With Left Ventricular Dysfunction Submitted to Coronary Artery Bypass Surgery

Resource links provided by NLM:

MedlinePlus related topics: Coronary Artery Bypass Surgery

U.S. FDA Resources

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:

Complicated clinical course after coronary artery bypass surgery [ Time Frame: within the first 30 days after surgery ] [ Designated as safety issue: No ]
Complicated clinical course defined as death within the first 30 days after surgery or ICU stay more than 4 days.


Enrollment:	87
Study Start Date:	January 2006
Study Completion Date:	March 2008
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Groups/Cohorts
Clinical course complicated course group (death within 30 days after surgery or ICU stay > 4 days) and uncomplicated course group (ICU stay ≤ 4 days).

Detailed Description:

Patients with left ventricular dysfunction are more susceptible to tissue hypoperfusion and presents more frequently both low cardiac output syndrome and systemic inflammatory response, what results in prolonged stay in intensive care unit (ICU), and higher mortality rates when compared to patients with normal ventricular function.

The early prediction of prolonged ICU stay through the detection of tissue hypoperfusion may improve the management of care and decrease morbidity of this particular group of patients. However, classic markers of tissue hypoxia as central venous saturation, base excess, lactate may not be predictors of outcome in cardiac surgery patients with left ventricular dysfunction.

The question addressed in this study is if less employed markers of tissue hypoperfusion as as venoarterial carbon dioxide partial pressure difference (ΔPCO2) and estimated respiratory quotient (eRQ) have predictive value of prolonged ICU stay in patients with left ventricular dysfunction submitted to coronary artery bypass surgery.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Adults undergoing coronary artery bypass surgery requiring the use of CPB

Criteria

Inclusion Criteria:

adults
left ventricular dysfunction (ejection fraction < 50%)
patients undergoing coronary artery bypass surgery requiring the use of Cardiopulmonary Bypass (CPB)

Exclusion Criteria:

renal failure (creatinine clearance lower than 40 ml/min/m2),
hepatic dysfunction
endocrinologic disorders
pulmonary disease
uncontrolled diabetes mellitus
a history of fever or infection within the week before surgery
previous anemia (hemoglobin ≤ 10.0 g/dL)

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01178866

Locations


Brazil
Heart Institute, Hospital of Clinics, São Paulo University Medical School
São Paulo, Brazil, 05403-000

Sponsors and Collaborators

University of Sao Paulo

Investigators


Principal Investigator:	Thiana Yamaguti, PhD	Heart Institute, Hospital of Clinics, São Paulo University Medical School
Study Chair:	José Otávio C. Auler Júnior, PhD/Chairman	Heart Institute, Hospital of Clinics, São Paulo University Medical School
Study Director:	Marilde A. Piccioni, PhD	Heart Institute, Hospital of Clinics, São Paulo University Medical School

More Information

Publications:

Mekontso-Dessap A, Castelain V, Anguel N, Bahloul M, Schauvliege F, Richard C, Teboul JL. Combination of venoarterial PCO2 difference with arteriovenous O2 content difference to detect anaerobic metabolism in patients. Intensive Care Med. 2002 Mar;28(3):272-7. Epub 2002 Feb 8.

Ranucci M, De Toffol B, Isgrò G, Romitti F, Conti D, Vicentini M. Hyperlactatemia during cardiopulmonary bypass: determinants and impact on postoperative outcome. Crit Care. 2006;10(6):R167.

Ranucci M, Isgrò G, Romitti F, Mele S, Biagioli B, Giomarelli P. Anaerobic metabolism during cardiopulmonary bypass: predictive value of carbon dioxide derived parameters. Ann Thorac Surg. 2006 Jun;81(6):2189-95.

Meregalli A, Oliveira RP, Friedman G. Occult hypoperfusion is associated with increased mortality in hemodynamically stable, high-risk, surgical patients. Crit Care. 2004 Apr;8(2):R60-5. Epub 2004 Jan 12.

Topkara VK, Cheema FH, Kesavaramanujam S, Mercando ML, Cheema AF, Namerow PB, Argenziano M, Naka Y, Oz MC, Esrig BC. Coronary artery bypass grafting in patients with low ejection fraction. Circulation. 2005 Aug 30;112(9 Suppl):I344-50.


Responsible Party:	Thiana Yamaguti/ Médica assistente da divisão de anestesiologia do InCor - HCFMUSP, University of Sao Paulo
ClinicalTrials.gov Identifier:	NCT01178866 History of Changes
Other Study ID Numbers:	HC517/04
Study First Received:	August 9, 2010
Last Updated:	August 9, 2010
Health Authority:	Brazil: National Committee of Ethics in Research

Keywords provided by University of Sao Paulo:


thoracic surgery myocardial revascularization left ventricular dysfunction tissue perfusion prognosis

Additional relevant MeSH terms:


Ventricular Dysfunction Ventricular Dysfunction, Left Cardiovascular Diseases Heart Diseases

ClinicalTrials.gov processed this record on February 27, 2015